- Q1 2024 Agenus Inc Earnings Call TranscriptMay 07, 2024$12.01 (-7.26%)Earnings
- Q4 2023 Agenus Inc Earnings Call and Corporate Update TranscriptMar 14, 2024$11.99 (-8.94%)Earnings
- Q3 2023 Agenus Inc Earnings Call and To Provide Corporate Update TranscriptNov 07, 2023$16.4 (+4.94%)Earnings
- Agenus Inc To Host Endpoints Webinar TranscriptOct 18, 2023
- Agenus Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Q1 2023 Agenus Inc Earnings Call TranscriptMay 09, 2023$30 (-5.66%)Earnings
- Agenus Inc at H.C. Wainwright BioConnect Investor Conference TranscriptMay 02, 2023
- Q4 2022 Agenus Inc Earnings Call TranscriptMar 14, 2023$35.13 (+4.68%)Earnings
- Agenus Inc at B Riley Securities Oncology Conference (Virtual) TranscriptJan 18, 2023
- Agenus Inc to Host “The Road Taken” R&D Event TranscriptNov 12, 2022
- Q3 2022 Agenus Inc Earnings Call TranscriptNov 08, 2022$43.77 (-6.69%)Earnings
- Q2 2022 Agenus Inc Earnings Call TranscriptAug 09, 2022$50.24 (-1.92%)Earnings
- Agenus Inc To Review Late-Breaking Botensilimab and Balstilimab Data Presented at ESMO World GI Congress TranscriptJun 29, 2022
- Q1 2022 Agenus Inc Earnings Call TranscriptMay 10, 2022$32.58 (+9.21%)Earnings
- Q4 2021 Agenus Inc Earnings Call TranscriptMar 01, 2022$50.83 (-4.07%)Earnings
- Q3 2021 Agenus Inc Earnings Call TranscriptNov 09, 2021$87.34 (+6.46%)Earnings
- Agenus Inc Business Update Call TranscriptOct 22, 2021
- Q2 2021 Agenus Inc Earnings Call TranscriptAug 09, 2021$105.98 (-4.09%)Earnings
- Agenus Inc at Raymond James Human Health Innovation Conference (Virtual) TranscriptJun 22, 2021
- Agenus Inc Discuss the Global Licensing Agreement Between Agenus and Bristol Myers Squibb - Corporate Call TranscriptMay 18, 2021
- Q1 2021 Agenus Inc Earnings Call TranscriptMay 06, 2021$55.35 (-4.24%)Earnings
- Q4 2020 Agenus Inc Earnings Call TranscriptMar 15, 2021$66.73 (+2.72%)Earnings
- Agenus Inc. - Special Call TranscriptFeb 11, 2021
- Agenus Inc at Jefferies Virtual London Healthcare Conference TranscriptNov 17, 2020
- Q3 2020 Agenus Inc Earnings Call TranscriptOct 29, 2020$73.01 (+0.81%)Earnings
- Agenus Inc. - Special Call TranscriptSep 21, 2020
- Q2 2020 Agenus Inc Earnings Call TranscriptAug 06, 2020$64.96 (-0.90%)Earnings
- Agenus Inc Annual Shareholders Meeting TranscriptJun 16, 2020
- Agenus Inc. - Special Call TranscriptJun 02, 2020
- Q1 2020 Agenus Inc Earnings Call TranscriptMay 07, 2020$49.85 (-3.79%)Earnings
- Q4 2019 Agenus Inc Earnings Call TranscriptMar 12, 2020$51.22 (-4.04%)Earnings
- Agenus Inc Corporate Analyst Meeting TranscriptFeb 20, 2020
- Agenus Inc. - Special Call TranscriptNov 15, 2019
- Q3 2019 Agenus Inc Earnings Call TranscriptNov 04, 2019$60.25 (+7.72%)Earnings
- Q2 2019 Agenus Inc Earnings Call TranscriptAug 08, 2019$51.03 (+18.72%)Earnings
- Agenus Inc Annual Shareholders Meeting TranscriptJun 19, 2019
- Q1 2019 Agenus Inc Earnings Call TranscriptMay 09, 2019$56.52 (+8.27%)Earnings
- Q4 2018 Agenus Inc Earnings Call TranscriptMar 14, 2019$58.68 (+1.01%)Earnings
- Agenus Inc. - Special Call TranscriptFeb 19, 2019
Agenus Inc To Host Endpoints Webinar Transcript
Hi, everyone. I'm Surani Fernando, your moderator for today's Endpoints News webinar. Today -- thanks for joining us for today's session. Sorry, my screen has just done something funny. Thanks for joining us at today's session titled Reactivating the Immune System against Cancer: The Next Immuno-Oncology Revolution.
We're sponsored today by Agenus, and I'm really excited to moderate today's expert panel. Joining us today, we have a great group of panelists. Steven O'Day, Chief Medical Officer at Agenus; Phuong Gallagher, Research Advocate, Training and Support manager at Fight Colorectal Cancer; Pashtoon Kasi, directive for Colorectal Cancer Research at Weill Cornell Medicine; and Benjamin Schlechter, senior physician in gastrointestinal cancer at Dana-Farber Cancer Institute.
Our goals for today's webinar are to share understandings of 3 things: Firstly, what botensilimab or BOT and balstilimab, BAL are showing in clinical trials across multiple tumor types. Secondly, understanding the broader potential of promising new and hopefully, more durable immune activators against
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)